Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation.
about
Celastrol, an NF-κB inhibitor, improves insulin resistance and attenuates renal injury in db/db miceDiabetic Kidney Disease: Pathophysiology and Therapeutic TargetsSuramin: a potential therapy for diabetic nephropathyPioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic ratsRosiglitazone prevents high glucose-induced vascular endothelial growth factor and collagen IV expression in cultured mesangial cells.Renoprotective effect of rosiglitazone through the suppression of renal intercellular adhesion molecule-1 expression in streptozotocin-induced diabetic rats.Jiangtang decoction ameliorate diabetic nephropathy through the regulation of PI3K/Akt-mediated NF-κB pathways in KK-Ay miceHomocysteine and Hypertension in Diabetes: Does PPARgamma Have a Regulatory Role?Transgenic overexpression of GLUT1 in mouse glomeruli produces renal disease resembling diabetic glomerulosclerosis.Inflammation in diabetic kidney diseaseThe peroxisome-proliferator activated receptor-γ agonist pioglitazone modulates aberrant T cell responses in systemic lupus erythematosus.Diabetic nephropathy - complications and treatment.Endogenous fructose production and fructokinase activation mediate renal injury in diabetic nephropathy.Targeting inflammation-induced obesity and metabolic diseases by curcumin and other nutraceuticalsHigh glucose induces CCL20 in proximal tubular cells via activation of the KCa3.1 channelA systems biology approach to understand the pathophysiological mechanisms of cardiac pathological hypertrophy associated with rosiglitazone.Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice.Inflammatory cytokines as predictive markers for early detection and progression of diabetic nephropathyDiabetes-induced renal injury in rats is attenuated by suraminSimilarities and differences between alpha-tocopherol and gamma-tocopherol in amelioration of inflammation, oxidative stress and pre-fibrosis in hyperglycemia induced acute kidney inflammation.Rosiglitazone reduces renal and plasma markers of oxidative injury and reverses urinary metabolite abnormalities in the amelioration of diabetic nephropathy.Long-term effects of rosiglitazone on the progressive decline in renal function in patients with type 2 diabetes.Change in albuminuria and eGFR following insulin sensitization therapy versus insulin provision therapy in the BARI 2D study.The effects of rosiglitazone on osteoblastic differentiation, osteoclast formation and bone resorption.Innate immune activation in obesity.Resveratrol Prevention of Diabetic Nephropathy Is Associated with the Suppression of Renal Inflammation and Mesangial Cell Proliferation: Possible Roles of Akt/NF-κB Pathway.Rosiglitazone increases cerebral klotho expression to reverse baroreflex in type 1-like diabetic rats.Tangshen Formula Attenuates Colonic Structure Remodeling in Type 2 Diabetic Rats.Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animalsPPARγ and chronic kidney disease.Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy.Renal epidermal growth factor receptor: its role in sodium and water homeostasis in diabetic nephropathy.The renoprotective actions of peroxisome proliferator-activated receptors agonists in diabetes.Microinflammation in the pathogenesis of diabetic nephropathy.Chronic kidney disease: targeting prostaglandin E2 receptors.Peroxisome proliferator activating receptor-γ and the podocyte.The citrus flavonoid hesperidin induces p53 and inhibits NF-κB activation in order to trigger apoptosis in NALM-6 cells: involvement of PPARγ-dependent mechanism.Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes.Rosiglitazone inhibits proliferation of renal proximal tubular cells via down-regulation of ERK and Akt.High glucose induced-macrophage activation through TGF-β-activated kinase 1 signaling pathway.
P2860
Q27323293-DDEB239C-20E3-4F73-8AAB-07D1A1876D15Q28086840-DC97FC38-D597-42D0-87AF-BA5B004322EEQ28536943-0099A982-39C1-48B3-8E13-950CD21BC0F8Q28580246-C845F88B-9BB4-4852-A496-BACCADB60A72Q29347056-F3B3AC91-E3E2-46B6-94B8-7041A463ED8CQ33413024-2C98B2B3-C47B-4833-A3E7-57E4C8434355Q33706208-E89B522A-4F87-4FFA-90F6-3D1EC1B9EFAEQ33953983-491C1347-7341-40B8-8C35-F632E841A4B2Q33995115-0D7E7298-0405-4512-8FC7-DACDCD069790Q34023543-0CE2CB74-CD81-41CD-B772-586E4D8C1243Q34284885-FBECFA5B-EC2B-47C6-97A5-92A10EE4324CQ34387952-CD5236F3-68BC-4A0E-98EC-2F2814721193Q34427632-BF661677-6A90-4B0F-BE88-BCF16629B074Q35129349-E97DAA00-F71C-4100-B661-329B3F1F42A1Q35147905-DA379C57-C8E3-4F96-A7BC-6AC833E9C8B9Q35189862-1DEEBC10-6E6C-4F6D-AAA9-9C48BA57239CQ35194026-D13FB21C-C14E-43F9-AA3E-E0925D116A2FQ36117573-B88A98B9-FFDF-46EE-958E-A912C0D78DA8Q36296876-CA8BA98E-6E87-4316-9941-07E2A4F15956Q36547055-F1FA58B3-E159-4AE0-825A-BA1867282ACBQ36956727-351AD9BC-4AF0-4FAB-801B-9D88910FEC85Q37320957-06203846-12AA-42AD-A321-C0A5DB344592Q37427000-EB4EE75C-1580-4335-B5CF-EFC52A1F97B4Q37461510-DC4407E8-9479-4C6F-8405-C0C43CBC3CB8Q37466096-9233F40F-7C24-49E8-96AD-DFBA80EFE235Q37615803-9F7676A9-DD10-4410-86C2-D0A15C856FA1Q37619096-D54C6A4F-37C8-48DB-AFB8-D6E7C7985201Q37682166-4A0BEBF0-F3EA-4AEA-B58A-6D48DC091C58Q37725539-2B25AA31-50E8-4E6D-9772-5F728562602DQ37777055-CB3D50FF-EA58-41EC-B2FA-5F90541F5DDFQ37780781-8E55BA57-EEF2-40BE-AA31-2F18D69277C3Q37820693-4B7AFB3B-F2FC-44AF-AAD9-45A0B556F6EAQ37997004-B75E80C7-74D3-466D-8BF0-3800236EB3F5Q38213048-8FA237AB-93D6-4442-ABE7-08A3DC418DC5Q38223323-A23232C3-04F0-40A9-B9F6-75DB7708AB03Q38815188-16DAA914-4F82-44C3-B74A-75C17DCE5500Q39569040-8DAFCA78-E1E8-4A2A-A457-8BC6CA52335AQ39604870-FE9E018B-319F-4A4A-9F9B-BC3BA5D2E87AQ39746277-0FD27256-0B1E-4133-867F-506226FA2F15Q39787653-DB349290-9B98-4744-8066-DE4DDC5AA8DE
P2860
Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Thiazolidinedione ameliorates ...... ition of NF-kappaB activation.
@en
Thiazolidinedione ameliorates ...... ition of NF-kappaB activation.
@nl
type
label
Thiazolidinedione ameliorates ...... ition of NF-kappaB activation.
@en
Thiazolidinedione ameliorates ...... ition of NF-kappaB activation.
@nl
prefLabel
Thiazolidinedione ameliorates ...... ition of NF-kappaB activation.
@en
Thiazolidinedione ameliorates ...... ition of NF-kappaB activation.
@nl
P2093
P2860
P1476
Thiazolidinedione ameliorates ...... ition of NF-kappaB activation.
@en
P2093
Daisuke Ogawa
Hirofumi Makino
Hitomi Usui
Kenichi Shikata
Kosuke Yozai
Sakiko Ohga
Shinichi Okada
Yasushi Shikata
P2860
P304
P356
10.1152/AJPRENAL.00288.2005
P50
P577
2006-12-26T00:00:00Z